Presenters
Francesca Ceccherini Silberstein, PhD
Annemarie M. Wensing, MD, PhD
Moderator
Douglas D. Richman, MD
January 31, 2024
9:00 AM - 10:30 AM PTOverview
Assessment of Needs
This webinar is useful for those who wish to utilize the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1 for the management of antiretroviral therapy (ART) in their patients with HIV. This webinar will review the principles of HIV drug resistance mutations and summarize what is currently known about resistance to antiretroviral drugs and products, including new and long-acting medications. The webinar includes an overview of how to read the IAS–USA mutation charts and explains the relevance of this information in clinical practice.
Learning Objectives
On completion of this activity, learners will be able to:
- Describe the principles and mechanisms of HIV drug resistance, and the impact of particular mutations
- Describe what is currently known about resistance to existing drugs, including new and long-acting medications
- Interpret and apply the information summarized in the 2022 IAS–USA Drug Resistance Mutations in HIV-1
Registration
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, January 31, 2023, 9:30 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Presenters
Dr Ceccherini-Silberstein reported consulting for Gilead Sciences, Inc, Merck Sharp & Dohme, Inc, and ViiV Healthcare; receiving research grants to her institution from Gilead Sciences, Inc, Merck Sharp & Dohme, Inc, and ViiV Healthcare. (Updated January 25, 2024)
Dr Wensing reported grants/grants pending to her institution from Gilead Sciences, Inc; consulting or advisor from Gilead Sciences, Inc, and ViiV Healthcare/GSK; and non-cash provision of medicines, equipment, or administrative support to her institution from ARK Diagnostics, Inc. (Updated January 25, 2024)
Planner/Reviewer
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated December 11, 2023)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated December 11, 2023)
COW Board
The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.5 contact hours (0.15 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-24-006-L02-P
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
PLATINUM SUPPORTERS
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
BRONZE SUPPORTERS
Janssen Therapeutics
Theratechnologies Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.